The Administrators of the Tulane Educational Fund

Xavier University of Louisiana

United States of America, As Represented by the Secretary of Agriculture

United States Department of Agriculture

Wake Forest University

University of Toledo

Duquesne University of the Holy Ghost

Tulane Educational Fund

Nume Health, LLC

Selvamedica, LLC

Tulane University

Matthew E Burow

Stephen M Boue

Guangdi Wang

Quan Jiang

Thomas E Wiese

Thomas E Cleveland

Deepak Bhatnagar

John A McLachlan

Paul W Erhardt

Patrick Flaherty

Shilong Zheng

Bruce Alan Bunnell

Suravi Chakrabarty

Darlene Monlish

Jane E Cavanaugh

Rahul Khupse

Van T Hoang

Thomas T Y Wang

Steven Elliott

Ven Subbiah

Peter Koepke

Jefferey G Sarver

Mark L Helman

Charles E Wood

Amy Strong

Patrick T Flaherty

Disclosed are anthranilic amide derivatives having the formula. Compositions are disclosed that include the anthranilic amide derivatives and the use of the anthranilic amide derivatives for the manufacture of a medicament. Further disclosed are methods of inhibiting or treating cancer, inhibiting or reversing an epithelial to mesenchymal cellular transition, and/or inhibiting MEK1/2 and/or MEK 5 enzymatic activity in a subject by administering to the subject an effective amount of a disclosed anthranilic amide derivative. 

Anthranilic amides and the use thereof

Disclosed are daidzein analogs having the formula (I). Also disclosed are compositions, include a disclosed daidzein analogs, methods of preventing or treating bone disease or bone injury and/or stimulating bone growth, in a subject that include administering to the subject an effective amount of disclosed daidzein analog. Disclosed are isolated mesenchymal stem cell that has been altered by treatment a disclosed daidzein analog, daidzein, glycinol, glyceollin I, or glyceollin II, to increase the osteogenic potential of the mesenchymal stem cells.

Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells

Provided are compositions for treatment of cancers, including breast cancer, comprising at least one novel daidzein analog, as well as methods of using the same for preventing or treating cancer or tumor growth.

Daidzein analogs as treatment for cancer

It has been discovered that irradiating the cut side of sugarcane billets, preferably 2-50 mm, with UVB or UVC light or combinations thereof initiates stilbene production, particularly resveratrol and piceatannol. In an embodiment the cut sides of sugarcane billets of a predetermined thickness are irradiated with Ultraviolet-C or Ultraviolet-B light or combinations thereof at an intensity and for a duration of time sufficient to produce a significant increase in a level of one or more stilbenes in the irradiated billets compared to a level of stilbenes in billets that are not irradiated; and the irradiated sugarcane billets are maintained for at least about three days up to about 20 days, to optimize stilbene levels.

Postharvest production and enhancement of resveratrol and piceatannol in sugarcane

Disclosed are methods of modulating the expression of genes linked to adipocytokine signaling, carbohydrate metabolism, fatty acid metabolism, arachidonic acid metabolism, PPAR signaling, insulin signaling, lipid metabolism, extracellular matrix (ECM)-receptor interaction, or combinations thereof, methods of treating hyperlipidemia, obesity, excessive cholesterol, cardiovascular disease, liver disease, diabetes, or combinations thereof, and methods of stimulating glucose uptake in an animal in need thereof, comprising administering a composition comprising at least one isolated glyceollin to said animal.

Compositions and methods for treating obesity and diabetes

Two distinct methods are disclosed and claimed for synthesizing glyceollin I plus glyceollin II as a mixture and as their pure forms. Stereochemical isomers and various synthetic intermediates are also synthesized and claimed for their novel compositions of matter. All compounds and their mixtures are claimed for use in formulations that are useful to treat or prevent cancer, or that have utility as selective estrogen receptor modulators, such formulations including enhanced or medical foods, dietary supplements and ethical pharmaceutical agents.

Methods for synthesizing glycinols, glyceollins I and II, compositions of selected intermediates, and therapeutic uses thereof

The flavonoid family of phytochemicals, particularly those derived from soy, has received attention regarding their hormonal activity and their effects on human health and disease. The types and amounts of these compounds in soy and other plants are controlled by both constitutive expression and stress-induced biosynthesis. The health benefits of soy may therefore be dependent upon the amounts of the various hormonally active phytochemicals present. We have identified increased biosynthesis of the isoflavonoid phytoalexin compounds, Glyceollins I, II and III, in soy plants grown under stressed conditions (elicited soy), which exhibit marked anti-estrogenic effects on ER function. Here we demonstrate that specific glyceollins, isolated from elicited soy, displayed anti-estrogenic activity, suppressing basal and estrogen stimulated colony formation of ER-positive estrogen dependent breast cancer cells and inhibiting ER-dependent gene expression of progesterone receptor (PgR) and stromal derived factor-1 (SDF1/CXCL12). Examining the effects of glyceollin on in vivo tumor formation/growth we demonstrate the ability of glyceollins to significantly suppress basal and estrogen-stimulated tumor growth of ER-positive MCF-7 breast and BG-1 ovarian carcinoma cells in ovariectomized female nude mice. We further demonstrate that the effects of glyceollins on suppression of tumor growth correlate with inhibition of estrogen stimulated PgR expression. In contrast to the uterotropic activity of tamoxifen the glyceollins displayed no uterine agonist activity. The Glyceollin (I-III) compounds may represent an important component of the health effects of soy as well as represent novel anti-estrogens useful in the prevention or treatment of breast and ovarian carcinoma.

Antiestrogenic glyceollins suppress human breast and ovarian carcinoma proliferation and tumorigenesis

A method of inhibiting COX-2, inhibiting NF-Kappa B activation, treating inflammation, or treating cancer may comprise administering a therapeutically effective amount of an extract ofMart. to a patient. A medicament as described herein may comprise a pharmaceutically acceptable vehicle and a therapeutically effective amount of an extract ofMart. suspended in the vehicle. A method of making an extract ofMart. may comprise creating a component solution by treatingMart. material with an extractor and a solvent and producing an extract by at least partially removing liquid from the component solution. An extract ofMart. may comprise components extracted using various solvents.

[object Object]

Growing community of inventors

Slidell, LA, United States of America

Matthew E Burow